|
Poll Results: Restrictions IBS patients are will to accept for access to IBS medications
(202 votes.)
|
| Medicines specific to IBS are accessible to a sufferer diagnosed
|
| only by a gastroenterologist and not by a family physician
| 41% (83)
| |
| by a family physician (or gastroenterologist)
| 59% (119)
| |
| A follow up appointment is
|
| mandatory with a gastroenterologist prior to a prescription refill
| 22% (44)
| |
| mandatory with a family physician (or gastroenterologist) prior to a prescription refill
| 38% (76)
| |
| unnecessary, but must receive a prescription refill from a gastroenterologist
| 15% (30)
| |
| unnecessary, but may receive a prescription refill from a family physician (or gastroenterologist)
| 26% (52)
| |
| Medication may be supplied
|
| one month at a time
| 26% (52)
| |
| three months at a time
| 54% (110)
| |
| six months at a time
| 14% (28)
| |
| unlimited
| 6% (12)
| |
| Physicians use of an IBS medication
|
| should not be used as a diagnostic tool for determining if a patient suffers from IBS
| 76% (154)
| |
| may be used as a diagnostic tool for determining if a patient suffers from IBS
| 24% (48)
| |
| Prior to receiving an IBS medication
|
| patient must sign a waiver limiting liability to pharmceutical or FDA agency
| 46% (93)
| |
| patient does not have to sign a waiver limiting liability to pharmceutical or FDA agency
| 54% (109)
| |
| Prior to receiving an IBS medication
|
| patient must agree to participate in a survey about use and side-effects sponsored by pharmaceutical and/or FDA agency
| 64% (130)
| |
| patient does not have agree to participate in a survey about use and side-effects sponsored by pharmaceutical and/or FDA agency
| 36% (72)
| |